US · FDA approval, new medicineOveporexton (Orzeyful)To treat narcolepsy type 1Approved 5 Aug 2026Source: US Food and Drug Administration
Sleep medicine · N Engl J Med · 2026-09-09In two phase 3 trials (273 people with narcolepsy type 1), oveporexton vs placebo improved MWT sleep latency at 12 weeks (+14.3 to 19.8 vs −0.4 to −0.8 min), with gains in sleepiness and cataplexy; adverse events 86–89% vs 43–54%.RCTn = 273Dauvilliers et al. Oveporexton for Narcolepsy Type 1 - Results from Two Phase 3 Trials
Neurology · JAMA Neurol · 2026-02-01Secondary analysis of a phase 2 RCT in 112 adults with narcolepsy type 1: oveporexton vs placebo over 8 weeks improved attention (PVT lapses -8.6 to -10.8 placebo-adjusted), memory and executive function across most doses.Secondary analysisn = 112Lammers et al. Effects of Oveporexton, an Orexin Receptor 2-Selective Agonist, on Cognition in Narcolepsy Type 1: A Secondary Analysis of a Randomized Clinical Trial